The patents on many well-known biological drugs will soon expire, giving drug developers the opportunity to make generic versions. Making an exact copy of these large, complex molecules, which include monoclonal antibodies, is almost impossible. But if developers can create similar versions (biosimilars) that can pass stringent tests, these important medicines could become available to many more people worldwide.
Learn more in this Nature Outline: https://www.nature.com/collections/iiijcgbdec
This Nature Video is editorially independent. It is produced with third party financial support. Read more about Supported Content here: https://partnerships.nature.com/commercial-content-at-nature-research/